Sophie E. Legge

Sophie E. Legge

Auto-generated profile, based on publicly available information

Sophie E. Legge

Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
APAntonio F. Pardiñas
Antonio F. Pardiñas
PHPeter Holmans
Peter Holmans
APAndrew J. Pocklington
Andrew J. Pocklington
VEValentina Escott-Price
Valentina Escott-Price
SRStephan Ripke
Stephan Ripke
JWJames T. R. Walters
James T. R. Walters

1 October 2015 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
BVBjarni J. Vilhjálmsson
Bjarni J. Vilhjálmsson
JYJian Yang
Jian Yang
HFHilary K. Finucane
Hilary K. Finucane
AGAlexander Gusev
Alexander Gusev
SLSara Lindström
Sara Lindström
WZWei Zheng
Wei Zheng

21 November 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CMChristian R Marshall
Christian R Marshall
PCPsychosis Endophenotypes International Consortium
Psychosis Endophenotypes International Consortium
DHDaniel P Howrigan
Daniel P Howrigan
DMDaniele Merico
Daniele Merico
BTBhooma Thiruvahindrapuram
Bhooma Thiruvahindrapuram
CCCNV and Schizophrenia Working Groups of the Psychiatric Genomics Consortium
CNV and Schizophrenia Working Groups of the Psychiatric Genomics Consortium
The CNV analysis group of the Psychiatric Genomic Consortium analyzes a large schizophrenia cohort to examine genomic copy number variants (CNVs) and disease risk. They find an enrichment of CNV burden in cases versus controls and identify 8 genome-wide significant loci as well as novel suggestive loci conferring either risk or protection to schizophrenia. Copy number variants (CNVs) have been strongly implicated in the genetic etiology of schizophrenia (SCZ). However, genome-wide investigation of the contribution of CNV to risk has been hampered by limited sample sizes. We sought to address this obstacle by applying a centralized analysis pipeline to a SCZ cohort of 21,094 cases and 20,227 controls. A global enrichment of CNV burden was observed in cases (odds ratio (OR) = 1.11, P = 5.7 × 10−15), which persisted after excluding loci implicated in previous studies (OR = 1.07, P = 1.7 × 10−6). CNV burden was enriched for genes associated with synaptic function (OR = 1.68, P = 2.8 × 10−11) and neurobehavioral phenotypes in mouse (OR = 1.18, P = 7.3 × 10−5). Genome-wide significant evidence was obtained for eight loci, including 1q21.1, 2p16.3 (NRXN1), 3q29, 7q11.2, 15q13.3, distal 16p11.2, proximal 16p11.2 and 22q11.2. Suggestive support was found for eight additional candidate susceptibility and protective loci, which consisted predominantly of CNVs mediated by nonallelic homologous recombination.

1 June 2018 in Cell
Verified
Journal Article
Closed access
DRDouglas M. Ruderfer
Douglas M. Ruderfer
SRStephan Ripke
Stephan Ripke
AMAndrew McQuillin
Andrew McQuillin
JBJames Boocock
James Boocock
ESEli A. Stahl
Eli A. Stahl
KKKenneth S. Kendler
Kenneth S. Kendler

1 November 2014 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
AGAlexander Gusev
Alexander Gusev
SLS. Hong Lee
S. Hong Lee
GTGosia Trynka
Gosia Trynka
HFHilary Finucane
Hilary Finucane
BVBjarni J. Vilhjálmsson
Bjarni J. Vilhjálmsson
SMSteve McCarroll
Steve McCarroll

1 February 2014 in The British Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
ERElliott Rees
Elliott Rees
JWJames T. R. Walters
James T. R. Walters
LGLyudmila Georgieva
Lyudmila Georgieva
AIAnthony R. Isles
Anthony R. Isles
KCKimberly D. Chambert
Kimberly D. Chambert
GKGeorge Kirov
George Kirov
Background: A number of copy number variants (CNVs) have been suggested as susceptibility factors for schizophrenia. For some of these the data remain equivocal, and the frequency in individuals with schizophrenia is uncertain.Aims: To determine the contribution of CNVs at 15 schizophrenia-associated loci (a) using a large new data-set of patients with schizophrenia (n= 6882) and controls (n= 6316), and (b) combining our results with those from previous studies.Method: We used Illumina microarrays to analyse our data. Analyses were restricted to 520 766 probes common to all arrays used in the different data-sets.Results: We found higher rates in participants with schizophrenia than in controls for 13 of the 15 previously implicated CNVs. Six were nominally significantly associated (P<0.05) in this new data-set: deletions at 1q21.1,NRXN1, 15q11.2 and 22q11.2 and duplications at 16p11.2 and the Angelman/Prader–Willi Syndrome (AS/PWS) region. All eight AS/PWS duplications in patients were of maternal origin. When combined with published data, 11 of the 15 loci showed highly significant evidence for association with schizophrenia (P<4.1×10−4).Conclusions: We strengthen the support for the majority of the previously implicated CNVs in schizophrenia. About 2.5% of patients with schizophrenia and 0.9% of controls carry a large, detectable CNV at one of these loci. Routine CNV screening may be clinically appropriate given the high rate of known deleterious mutations in the disorder and the comorbidity associated with these heritable mutations.